At first I wrote off IPA.v as it shot up from $10 to over $25 post 5:1 rollback and listed promptly on NASDAQ, where markets are bigger and dollars are larger.
But I took a further look at the insiders, strong scientists and serious board, and I changed my mind a bit.
precise.com.IPA’s CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television
VICTORIA, October 6, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, is scheduled to appear as a guest on BNN Television on Wednesday, Oct 7th, at approximately 11:30 am ET.
In light of recent events pertaining to President Trump’s SARS-CoV-2 infection, Dr. Bath will discuss current therapeutics in the clinic as well as IPA’s Polytope™ therapy and vaccine strategies. The Company believes it has launched the most comprehensive and diverse global antibody discovery program, which, unlike current approaches, is designed to provide durable, long-lasting treatment for the entire population and potential virus mutations.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company’s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise’s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact solutions@immuno
Management / Jennifer Bath doesn't own a lot but these are all ex-Pharma major senior execs.
Lot of real R&D and sales BD team who I imagine are chasing Merck and GSK all day for contract outsource deals for scientists.
Lower overhead and higher chance of success, hard to argue
The Board, and previous promoters/smallcap brokers own enough they are insiders.
PAUL ANDREOLA who runs well known small cap digest (SCD) holds nearly 1.2 million shares (stocks at $20/share)
MIKO MALBERG another insider holds 800k shares and has been selling down lately at recent highs.
As mentioned before - this is a contract research business - from what I can understand they are the outsource research R&D firm for big pharma.
revenue has clearly picked up - not to mention tons of research grants and gov assistance due to COVID exposure and related R&D deals.
The spinoout parent co is NameSilo tech (URL:TSXV_ which still holds 3% of a now $400M company.
Company is cashed up and recent quarters were generating $3-4M revenue with $450-900K EBITDA range.
Uplist to NASDAQ was just Dec 30.
I thikn there's a good run way in 2021 - obv not quite a penny stock but worth a look for those who wants some biotech smallcap exposure